Posted by Michael Wonder on 14 Aug 2020
ANTI-PD-1/CTLA-4 bi-specific antibody (AK104) of Akeso granted FDA fast track designation for recurrent and metastatic cervical cancer
13 August 2020 - Akeso today announced that the U.S. FDA has granted fast track designation for AK104, a novel anti-PD-1/CTLA-4 bi-specific antibody, as monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer who have disease progression on or after platinum-based chemotherapy.
AK104 is a potential next-generation, first-in-class humanised IgG1 tetrameric bi-specific antibody drug candidate that is developed in house by Akeso, is designed to achieve preferential binding to tumour infiltrating lymphocytes rather than normal peripheral tissue lymphocytes.
